|
| |
| | | 69592 | | 21.05.2026 | | Bristol-Myers Squibb SA | | | | | | | 20.05.2031 | | | | | | | | | | 06.07.30. | | IP |
| | Seq.-No. | Product | Description | Galenic form | ATC-classification | |
|---|
| 01 | Reblozyl 25 mg | Pulver zur Herstellung einer Injektionslösung | Dry substance (Luspaterceptum 25 mg) | B03XA06 | | | 02 | Reblozyl 75 mg | Pulver zur Herstellung einer Injektionslösung | Dry substance (Luspaterceptum 75 mg) | B03XA06 | |
|
|
|
